Cetrelimab

Overview

Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer	2025/06/18	NCT07027514	Phase 1	Not yet recruiting	Ankyra Therapeutics, Inc
CD8 PET Imaging in Metastatic Solid Tumours	2024/08/02	NCT06534190	Phase 2	Recruiting	University Medical Center Groningen
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations	2024/07/22	NCT06511648	Phase 2	Recruiting	Spanish Oncology Genito-Urinary Group
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors	2024/03/15	NCT06311578	Phase 1	Recruiting	Johnson & Johnson Enterprise Innovation Inc.
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	2023/11/03	NCT06116786	Phase 1	Recruiting	Johnson & Johnson Enterprise Innovation Inc.
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer	2023/06/18	NCT05908734	Phase 1	Recruiting	Janssen Research & Development, LLC
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer	2023/04/19	NCT05818683	Phase 1	Recruiting	Janssen Research & Development, LLC
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)	2023/02/06	NCT05714202	Phase 3	Active, not recruiting	Janssen Research & Development, LLC
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection	2022/02/16	NCT05242445	Phase 1	Completed	Janssen Research & Development, LLC
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer	2021/06/15	NCT04926181	Phase 2	Terminated	Rahul Aggarwal

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Immune Checkpoint Inhibitors Emerge as Standard of Care for Early-Stage NSCLC, New Data Shows

3 months ago

Neoadjuvant, adjuvant, and perioperative PD-L1 immune checkpoint inhibitors have become standard treatment options for early-stage non-small cell lung cancer, significantly improving survival outcomes compared to conventional approaches.

DelveInsight Report: Over 50 Pipeline Drugs in Development for Urothelial Carcinoma Treatment

5 months ago

DelveInsight's latest pipeline analysis reveals 40+ pharmaceutical companies actively developing 50+ therapeutic candidates for urothelial carcinoma treatment, indicating robust research activity in this space.

J&J Seeks FDA Approval for TAR-200 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

6 months ago

Johnson & Johnson has initiated a New Drug Application (NDA) submission to the FDA for TAR-200.

TAR-200 Shows Promising Efficacy and Tolerability in BCG-Unresponsive NMIBC

7 months ago

TAR-200, an intravesical gemcitabine-releasing system, demonstrates high complete response rates in patients with non-muscle-invasive bladder cancer (NMIBC) unresponsive to BCG therapy.

XOMA Royalty Reports Q3 2024 Financial Results, Highlights Portfolio Expansion

8 months ago

• XOMA Royalty's portfolio expanded with FDA approval of Zevra's MIPLYFFA™ (arimoclomol) for Niemann-Pick disease Type C, marking its sixth commercial asset. • The company acquired a 50% economic interest in Twist Bioscience’s portfolio of over 60 licensed early-stage assets, diversifying its early-stage investments. • XOMA Royalty reported cash receipts of $9.9 million for Q3 2024 and $42.3 million for the first nine months, demonstrating strong financial performance. • Agenus Royalty Purchase Agreement led to a one-time, non-cash impairment charge of $14.0 million.

AI-Powered Research

Premium Access